Trump administration rejects idea of testing the country back to pre-pandemic normal

Trump administration rejects idea of testing the country back to pre-pandemic normal
A further massive increase in the availability of tests for the coronavirus could functionally end the pandemic and return life to normal, many public health experts and economists say. The Trump administration's coronavirus testing czar, though, rejects the idea.

“You never have enough tests because it's not one and done,” said Peter Pitts, the former Food and Drug Administration associate commissioner and president and co-founder of the think tank, the Center for Medicine in the Public Interest. “It's not as though I get tested on the list, I'll never need to be tested again. People will need to be tested many times.”

In the view of many public health experts, widespread testing for both symptomatic and asymptomatic people would allow many people to return to their pre-pandemic lives. Today, in contrast, the Centers for Disease Control and Prevention recommends that testing should only be used for people who have symptoms or were exposed to the virus or for public surveillance. The approach has limited the spread of the disease. But outside experts argue that the administration should prioritize the development and distribution of cheap, easy-to-use tests so that people could test themselves regularly. Doing so would allow the vast majority of people to go about their lives without fear of spreading the disease, they say.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving patent protection discourages cutting-edge research investments, which in turn produce breakthrough treatments no...  Read more

'I'm hopeful for the future': Alzheimer's drug approved by FDA

'I'm hopeful for the future': Alzheimer's drug approved by FDA

Peter Pitts of CMPI and Dr. Ronald Petersen of the Mayo Clinic discuss the FDA's approval of aducanumab...  Read more

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

DRUGWONKS BLOG